Autor: Lanju Zhang

About the Editors: Lanju Zhang is Director in Statistics and Research Fellow at the Department of Data and Statistical Sciences at Abb Vie. He is leading a group providing statistical support to emerging immunology clinical programs. Prior to that, he was Head of Nonclinical Statistical Group at Abbvie and Med Immune. His research interests include adaptive design, multi-region clinical trials, real world evidence, and nonclinical statistics. He has published two books (both with Springer) and more than 30 papers. He is an associate editor of Journal of Biopharmaceutical Statistics. He received his Ph D in Statistics in 2005 from University of Maryland Baltimore County. Ding-Geng Chen is a Fellow of American Statistical Association and currently the Wallace H. Kuralt Distinguished Professor at the University of North Carolina at Chapel Hill. He was a professor at the University of Rochester and the Karl E. Peace Endowed Eminent Scholar Chairin Biostatistics at Georgia Southern University. He is also a senior statistics consultant for biopharmaceuticals and government agencies with extensive expertise in Monte-Carlo simulations, clinical trial biostatistics and public health statistics. Professor Chen has more than 150 referred professional publications and co-authored and co-edited 18 books on clinical trial methodology, meta-analysis and public health applications and he has been invited nationally and internationally to give speeches on his research. Hongmei Jiang is an associate professor of statistics at Northwestern University. Her current research focuses on developing statistical methods and computational algorithms to analyze and understand the massive amount of data generated by high throughput biological technologies, such as microarray and next generation sequencing technologies. She has published over 40 research articles in statistics and biostatistics research fields. She was the Co-Chair for the 26th ICSA Applied Statistics Symposium, which was successfully held in Chicago in June 2017. Gang Li is a scientific director, RWE Analytics at Janssen R&D US. He is an elected fellow of the American Statistical Association. Dr. Li received his Ph D from the State University of New York at Binghamton. Gang has genuine interest in statistical research and has published a number of papers on multi-regional clinical trials, adaptive design and dose finding, and non-inferiority study design in leading statistical journals. Hui Quan received his Ph D in statistics from Columbia University in 1990. He is currently an associate VP and global head of the methodology group at the Biostatistics and Programming Department of Sanofi. He has 26 years of pharmaceutical industry experience in many therapeutic areas ranging from early phase to Phase IV studies. He has published 93 papers including 69 statistical papers. He is a co-author/co-editor of two books. He has also served as an associate editor for two journals. His research interests include multivariate analysis, safety analysis, multiplicity adjustment, missing data handling, adaptive design, integrated data analysis, modeling and simulation, benefit/risk assessment and multi-regional clinical trials. He was elected as a fellow of the American Statistical Association in 2008.